In addition, the median PFS of first-line bevacizumab combined with erlotinib or afatinib in advanced EGFR-mutated NSCLC patients shown by previous studies seems not inferior to first-line osimertinib (13–16). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.